| 崔天祥,孙建国,张玉晶.三种治疗方式对早期原发性胃弥漫大B细胞淋巴瘤的对比分析[J].中华放射医学与防护杂志,2015,35(7):514-517 |
| 三种治疗方式对早期原发性胃弥漫大B细胞淋巴瘤的对比分析 |
| Comparison of three methods of treatments in patients with early stage primary gastric diffuse large-B cell lymphoma |
| 投稿时间：2014-10-20 |
| DOI：10.3760/cma.j.issn.0254-5098.2015.07.008 |
| 中文关键词: 原发性胃弥漫大B细胞淋巴瘤 早期 治疗方式 疗效 |
| 英文关键词:Primary gastric diffuse large B cell lymphoma Early stage Methods of treatment Curative effect |
| 基金项目: |
|
| 摘要点击次数: 2691 |
| 全文下载次数: 2437 |
| 中文摘要: |
| 目的 分析早期原发性胃弥漫大B细胞淋巴瘤(PG-DLBCL)不同治疗方式疗效差别,探讨PG-DLBL患者最佳治疗方法。方法 回顾性分析2000年8月至2011年10月经胃镜活检或手术病理证实的66例早期PG-DLBL患者资料,分为单纯化疗组21例、放疗联合化疗组22例和手术联合化疗组23例,比较3组预后情况。结果 单纯化疗组、放疗联合化疗组、手术联合化疗组的完全缓解率分别为47.6%、77.3%、65.2%差异无统计学意义(P > 0.05);3组66例患者中位无进展生存期分别为61.5、90.4和79.1个月,差异有统计学意义(χ2=6.726, P=0.035);3年生存率分别为81.6%、90.5%、82.6%,5年生存率分别为72.5%、90.5%、82.6%,但差异无统计学意义(P > 0.05)。结论 化疗联合放疗能获得更高的无进展生存时间,不增加患者的不良反应,可作为早期PG-DLBCL的首选治疗方式。 |
| 英文摘要: |
| Objective To compare the therapeutic effects of three therapeutics to earlier primary gastric diffuse large B cell lymphoma(PG-DLBCL). Methods By reviewing a data-base of 66 patients with earlier PG-DLBCL from Aug 2000 to Oct 2011 were enrolled, patients were divided into chemotherapy alone(21 cases), radiotherapy combined with chemotherapy(22 cases) and surgery followed chemotherapy group(23 cases), and to comparing the prognosis of the three therapeutics. Results The complete remission rates(CR) of the three groups was 47.6%, 77.3%, 65.2%(P > 0.05). The median progression-free survival(PFS)of the three groups in 66 patients was 61.5, 90.4 and 79.1 months, the radiotherapy combined group was proven to be significantly better than chemotherapy alone group and surgery followed chemotherapy group(χ2=6.726, P<0.05). The 3-year survival rate of the three groups was 81.6%, 90.5% and 82.6%. The five year survival rate was 72.5%, 90.5%, 82.6%. There was no significant difference(P>0.05) in 3-year survival rate and 5-year survival rate. Conclusions Radiotherapy combined with chemotherapy can significantly improve the PFS without increasing the risk of other adverse outcomes, and could be the first treatment way for the earlier PG-DLBCL. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|